All In Biotech

Drug Trial Radar · NCT05621811

Different Doses of Naronapride vs. Placebo in Gastroparesis

Double-blind, Randomised, Placebo-controlled, Dose-finding Phase IIb Trial to Evaluate the Efficacy, Safety, and Tolerability of a 12-week-treatment With Naronapride in Adult Participants With at Least Moderate Idiopathic or Diabetic Gastroparesis

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 328 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

328

Actual

Start

Jan 3, 2023

Primary completion

Aug 12, 2025

Study completion Sep 4, 2025

Sponsor

Lead sponsor
Dr. Falk Pharma GmbHIndustry
Sponsor type
Industry
First posted
Nov 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.

Conditions

  • Gastroparesis

Interventions

  • NaronaprideDrug

    Naronapride is a gut lumen active, bifunctional 5HT-4 agonist//D2 antagonist

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary Total Score at Week 12Time frame: Baseline and Week 12

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Dr Falk Investigational Site

    Chula Vista, California

  • Dr Falk Investigational Site

    Lomita, California

  • Dr Falk Investigational Site

    Clearwater, Florida

  • Dr Falk Investigational Site

    Doral, Florida

  • Dr Falk Investigational Site

    Hollywood, Florida

  • Dr Falk Investigational Site

    Maitland, Florida

  • Dr Falk Investigational Site

    Miami, Florida

  • Dr Falk Investigational Site

    Miami, Florida

  • Dr Falk Investigational Site

    Viera, Florida

  • Dr Falk Investigational Site

    Kansas City, Kansas

  • Dr Falk Investigational Site

    Topeka, Kansas

  • Dr Falk Investigational Site

    Crestview Hills, Kentucky

  • Dr Falk Investigational Site

    Houma, Louisiana

  • Dr Falk Investigational Site

    Marrero, Louisiana

  • Dr Falk Investigational Site

    Flint, Michigan

  • Dr Falk Investigational Site

    Flint, Michigan

  • Dr Falk Investigational Site

    New York, New York

  • Dr Falk Investigational Site

    Cleveland, Ohio

  • Dr Falk Investigational Site

    Tulsa, Oklahoma

  • Dr Falk Investigational Site

    Philadelphia, Pennsylvania

  • Dr Falk Investigational Site

    Cordova, Tennessee

  • Dr Falk Investigational Site

    Nashville, Tennessee

  • Dr Falk Investigational Site

    Harlingen, Texas

  • University of Leuven

    Leuven, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.